Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients.
Inivata – non-invasive tumour analysis from circulating DNA
Cancers evolve over time, especially in response to treatment, and identifying these changes is a challenge for traditional pathology. Circulating cell-free DNA offers the possibility to assess the cancer state in real-time using a non-invasive ‘liquid biopsy’ that collects tumour DNA from the bloodstream. Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumour DNA (ctDNA) which can be collected through a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored and treated.
Inivata is applying its enhanced TAm-Seq approach and cutting-edge technologies to address critical clinical decision points in cancer care and cancer drug development, alongside pharmaceutical partners, leading clinicians and academic groups. TAm-Seq provides the ability for sensitive next generation sequence analysis of sizable regions in the genome including entire genes or exons, by tiling short amplicons with proprietary processing, adapters, and analysis that allow effective correction of background. Its proprietary technologies allow improved sensitivity and coverage of larger gene panels. Inivata aims to further optimize and standardize these methods, and to deploy them in multiple clinical studies.
Inivata is based in Cambridge (UK) and its scientific founders are leading figures in the ctDNA field. Management Team is composed by Michael Stocum, Nitzan Rosenfeld, Amanda Bettison, James Brenton, Tim Forshew, Davina Gale, Vincent Plagnol, John Beeler, Emma Green and Simon Peace. Inivata works with leaders in industry and academic research to develop new clinical applications for ctDNA analysis which will bring real benefits to physicians, patients, pharmaceutical companies and payers.
More about Inivata : http://inivata.com/